Neurosteroid Withdrawal Model of Perimenstrual Catamenial Epilepsy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Purpose: Perimenstrual catamenial epilepsy, the increase in seizure frequency that some women with epilepsy experience near the time of menstruation, may in part be related to withdrawal of the progesterone metabolite allopregnanolone, an endogenous anticonvulsant neurosteroid that is a potent positive allosteric γ‐aminobutyric acid A (GABA A) receptor modulator. The objective of this study was to develop an animal model of perimenstrual catamenial epilepsy for use in evaluating drug‐treatment strategies. Methods: A state of prolonged high serum progesterone (pseudopregnancy) was induced in 26‐day‐old female rats by sequential injection of pregnant mares' serum gonadotropin and human chorionic gonadotropin. Neurosteroid withdrawal was induced by treatment with finasteride (100 mg/kg, i.p.), a 5α‐reductase inhibitor that blocks the conversion of progesterone to allopregnanolone. Plasma progesterone and allopregnanolone levels were measured by gas chromatography/electron capture negative chemical ionization mass spectrometry. Seizure susceptibility was evaluated with the convulsant pentylenetetrazol (PTZ). Results: Plasma allopregnanolone levels were markedly increased during pseudopregnancy (peak level, 55.1 vs. control diestrous level, 9.3 ng/mL) and were reduced by 86% 24 h after finasteride treatment (6.4 ng/mL). Progesterone levels were unaffected by finasteride. After finasteride‐induced withdrawal, rats showed increased susceptibility to PTZ seizures. There was a significant increase in the number of animals exhibiting clonic seizures when challenged with subcutaneous PTZ (60 mg/kg) compared with control pseudopregnant animals not undergoing withdrawal and nonpseudopregnant diestrous females. The CD 50 (50% convulsant dose) was 46 mg/kg, compared with 73 mg/kg in nonwithdrawn pseudopregnant animals and 60 mg/kg in diestrous controls. The threshold doses for induction of various seizure signs, measured by constant intravenous infusion of PTZ, were reduced by 30–35% in neurosteroid‐withdrawing animals compared with control diestrous females. No change in threshold was observed in pseudopregnant rats treated from days 7 to 11 with finasteride, demonstrating that high levels of progesterone alone do not alter seizure reactivity. Conclusions: Neurosteroid withdrawal in pseudopregnant rats results in enhanced seizure susceptibility, providing an animal model of perimenstrual catamenial epilepsy that can be used for the evaluation of new therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Purdy, R. H., Morrow, A. L., Moore, P. H., & Paul, S. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4553 · Cited by 951
GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid
Smith, S. S., Gong, Q. H., Hsu, F.-C., Markowitz, R. S., ffrench-Mullen, J. M. H., & Li, X. (1998) · Nature · doi:10.1038/31948 · Cited by 564 · cited 2×
“(41,44,45) have proposed that progesterone withdrawal is accompanied by alterations in the expression of GABAA-receptor subunits and a consequent change in GABAA-receptor properties that causes reduced inhibition and an overall increase in brain excitability.”
BackgroundProgesterone metabolite allopregnanolone in women with premenstrual syndrome
RAPKIN, A., MORGAN, M., GOLDMAN, L., BRANN, D., SIMONE, D., & MAHESH, V (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00417-1 · Cited by 376
Progesterone therapy in women with complex partial and secondary generalized seizures
Herzog, A. G. (1995) · Neurology · doi:10.1212/wnl.45.9.1660 · Cited by 218
Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy
Reddy, D. S., & Rogawski, M. A. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.10200.x · Cited by 130 · cited 2×
“In view of the considerable evidence linking perimenstrual catamenial seizure exacerbations to the sharp decline in allopregnanolone levels at the time of menstruation, the pseudopregnancy–finasteride withdrawal model may be useful for the evaluation of therapeutic approaches to the treatment of catamenial epilepsy (5…”
BackgroundSelf-citationThe history of benzodiazepine dependence: A review of animal studies
File, S. E. (1990) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80214-3 · Cited by 101
Cited by
Maguire, J. L., Stell, B. M., Rafizadeh, M., & Mody, I. (2005) · Nature Neuroscience · doi:10.1038/nn1469 · Cited by 644
(2010) · Progress in Brain Research · doi:10.1016/b978-0-444-53630-3.00008-7 · Cited by 584
Neurosteroids: biochemistry and clinical significance
Mellon, S. H., & Griffin, L. D. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00503-3 · Cited by 538
Reddy, D. S., & Rogawski, M. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03795.2002 · Cited by 279
Self-citationScharfman, H. E., Mercurio, T. C., Goodman, J. H., Wilson, M. A., & MacLusky, N. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-37-11641.2003 · Cited by 271
Metadata
- Authors
- Reddy, D. S., Kim, H., & Rogawski, M. A.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2001-03-09
- Volume
- 42
- Issue
- 3
- Pages
- 328-336
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2051056852
- Cited by
- 157
- References
- 6
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurosteroid Withdrawal Model of Perimenstrual Catamenial Epilepsy. https://app.cochat.ai/papers/10.1046/j.1528-1157.2001.10100.x
- The paper
- Reddy, D. S., Kim, H., & Rogawski, M. A. (2001). Neurosteroid Withdrawal Model of Perimenstrual Catamenial Epilepsy. Epilepsia. https://doi.org/10.1046/j.1528-1157.2001.10100.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.